Question explored with the scientific record
What was the exact reason why avacopan was withdrawn from the Uk market
The retrieved evidence does not mention avacopan being withdrawn from the UK market.
The records show avacopan was studied for ANCA-associated vasculitis, with a 2017 trial finding it could replace high-dose glucocorticoids [1]. A 2026 case report describes its successful use in a life-threatening case [3]. A 2025 study examined its mechanism of action on neutrophils [2].
None of the 22 retrieved records state that avacopan was withdrawn from the UK market, nor do they give a reason for any such withdrawal. The retrieval contains no regulatory filings, no MHRA announcements, and no commercial discontinuation notices for this drug.
My call: the question cannot be answered from the evidence retrieved. Confidence: not clear.
Sources used 3
-
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
This study demonstrates that avacopan, a selective C5a receptor inhibitor, can effectively replace high-dose glucocorticoids in the treatment of ANCA-associated vasculitis without compromising efficacy, as shown in a randomized, placebo-controlled trial involving 67 patients.
DOI: 10.1681/asn.2016111179 -
The free fatty acid 2 receptor regulates the activation potency of C5a and the sensitivity to the antagonist avacopan
TNF-primed human neutrophils reveal that an FFA2R allosteric modulator (Cmp58) increases the potency of C5a to activate NADPH oxidase via transactivation of FFA2R, demonstrates a two-signal receptor interaction with C5aR1 and FFA2R, and establishes a hierarchical signaling model…
DOI: 10.1101/2025.10.28.685092 -
Avacopan for severe pulmonary hemorrhage requiring extracorporeal membrane oxygenation in a patient with MPO-ANCA positive vasculitis
A life-threatening MPO-ANCA vasculitis case with diffuse alveolar hemorrhage requiring ECMO was successfully treated with avacopan plus standard immunosuppression, enabling rapid taper and withdrawal of prednisone within six months.
DOI: 10.1007/s13730-025-01068-0